News about Drug Discovery & Development

Strides Gets FDA Approval for Theophylline Extended-Release Tablets

Theophylline Extended-Release Tablets, 300 mg and 450 mg have a combined market size of ~USD 11.5 million, with the 300 mg dosage contributing ~USD 10.8 million.

Drug Discovery & Development | 06/09/2024 | By Aishwarya |  488

Alembic Pharma Receives Final FDA Approval for Albendazole Tablets

Albendazole tablets are indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium.

Drug Discovery & Development | 05/09/2024 | By Aishwarya |  914

Lilly Signs Deal with EVA Pharma to Expand Access to baricitinib

This collaboration is part of the Lilly 30x30 initiative, which aims to improve access to quality health care for 30 million people living in resource-limited settings annually by 2030.

Drug Discovery & Development | 05/09/2024 | By Aishwarya |  599

Nxera Pharma to Get USD 35 Million from Neurocrine for Phase 2 Trial with NBI- '568

The NBI-’568-SCZ2028 dose-finding study met its primary endpoint for the once-daily 20 mg dose and was generally safe and well tolerated at all doses studied, supporting Neurocrine’s intentions to advance NBI- ‘568 into Phase 3 clinical trials in early 2025.

Drug Discovery & Development | 03/09/2024 | By Aishwarya |  343

Novavax 2024-2025 Formula COVID-19 Vaccine Gets EUA for Use in US

Pre-filled syringes of the vaccine will be available in thousands of locations, including retail and independent pharmacies and regional grocers, following the Center for Biologics Evaluation and Research release of vaccine batches.
<br />

Drug Discovery & Development | 02/09/2024 | By Aishwarya |  841

Natco Pharma Submits ANDA for Generic Version of TABRECTA

Natco claims to be the first company to have filed a substantially complete ANDA containing a paragraph IV certification for this product and expects to be eligible for 180 days of sole marketing exclusivity at the time of the potential launch of the product under certain circumstances.

Drug Discovery & Development | 31/08/2024 | By Aishwarya |  863

Zydus Gets Final Approval from USFDA for Scopolamine Transdermal System

Scopolamine Transdermal System is indicated to prevent nausea and vomiting after anaesthesia, narcotic pain medicines, and surgery.

Drug Discovery & Development | 31/08/2024 | By Aishwarya |  602

Biocon Biologics Signs License Deal with Janssen for Bmab 1200

Under the terms of this settlement agreement, Biocon Biologics has resolved patent disputes with Janssen to secure market entry dates in Europe, the UK, Canada, and Japan. Regulatory filings in these markets are currently under review.

Drug Discovery & Development | 29/08/2024 | By Aishwarya |  468

Alembic Gets FDA Approval for Betamethasone Valerate Foam

Betamethasone valerate foam, 0.12 percent, is a medium potency topical corticosteroid indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp.

Drug Discovery & Development | 27/08/2024 | By Aishwarya |  475

BioIVT Acquires ZenBio to Expand its Pharmaceutical Portfolio

Together, BioIVT and ZenBio will offer an expanded portfolio of skin-based expertise, primary cell and exosome isolation, as well as blood products for pharmaceutical and cosmetics companies.

Drug Discovery & Development | 26/08/2024 | By Aishwarya |  304